Announcements Trials
Browse Landscape

Status

Available 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 421Observational 60Expanded_access 3

Sponsor

Cancer Type

Dermatologic 21Gastrointestinal 4Thoracic 3Gynecologic 3Genitourinary 3CNS 3Sarcoma 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 28Carcinoma, Renal Cell 7Pancreatic Neoplasms 6Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Sarcoma 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 3Melanoma 3Stomach Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Head and Neck Neoplasms 2Glioblastoma 2Chondrosarcoma 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Wilms Tumor 1Urologic Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prostatic Diseases 1

Interventions

ulixertinib 1pegilodecakin 1balstilimab 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × Genitourinary × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡